The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Participants with confirmed Sickle Cell Disease.
Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
Willing and able to provide informed consent
Ability to comply with study related evaluations and follow-up visits.
None
Children from 6 months to 6 years old with Sickle Cell Disease who receive medical care in Cincinnati, Ohio; Accra, Ghana; and Mwanza, Tanzania will be eligible.
Cohort
Prospective
Not listed
Measles Seroconversion Rates 8 Weeks After MV1 and MV2 Vaccinations
Sample analysis of 126 participants 8-weeks post complete measles vaccination.
Measles Seroconversion Rates 4 Weeks After MV1 Vaccination
Sample analysis of participants' seroconversion rates 4-weeks post first vaccination.
Measles Seroconversion Rates 4 Weeks after MV2 Vaccination
The sample analysis of participant's seroconversion rates 4-weeks post second vaccination.
Variables Associated with Measles Vaccine-induced Antibody Response
Identify participant's demographic, clinical history, and sickle cell treatments as variables to measles antibody response.
Modalities for Sample Analysis
Compare sample analysis results between the gold standard (serum or plasma) and Mitra sample using dried blood spot or whole blood.
Click on the lead sponsor to view all of their trials.
Children's Hospital Medical Center, Cincinnati
Lead sponsor
Thrasher Research Fund
Collaborator
National Institutes of Health (NIH)
Collaborator
